Immunic, Inc. (IMUX)

NCM – Real vaqt narxi. Valyuta: USD

15.30

+0.23 (1.53%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

15.20

-0.10 (-0.65%)

Bozordan keyin: Jun 26, 2026, 7:59 PM EDT

10.06.2026

Immunic to Participate in Investor, Industry and Scientific Conferences in June

NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June: June 15-16: H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit.

28.05.2026

Immunic presents new vidofludimus calcium data at multiple sclerosis conference

Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, North Carolina, including a late-breaking analysis of its lead drug candidate vidofludimus calcium in patients with progressive multiple sclerosis. The late-breaking poster introduced a novel unified endpoint called Confirmed Disability Change, designed to capture both disability worsening and improvement within a single statistical framework.

28.05.2026

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis – – Additional CALLIPER Data Further Highlight Vidofludimus Calcium's Favorable Safety and Tolerability Profile; Patient-Reported Outcomes Assessments Show No Negative Impact on Mood – NEW YORK, May 28, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the presentation of one late-breaking and two additional posters highlighting additional data from its phase 2 CALLIPER trial evaluating lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) in patients with progressive multiple sclerosis (PMS) at the 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, taking place May 27-29, 2026 in Charlotte, NC. All poster presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.

27.05.2026

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its chief executive officer as the company advances its multiple sclerosis treatment candidate through late-stage development and prepares for potential commercialization. He succeeds Daniel Vitt, who will continue to oversee scientific strategy and portfolio advancement while remaining on the company's board of directors.

27.05.2026

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus® – – Will Leverage Senior Global Executive and Commercial Experience to Support Immunic's Transition Toward a Commercial-Stage Multiple Sclerosis Company – NEW YORK, May 27, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of distinguished biopharmaceutical executive Erik Lundgren as Chief Executive Officer, effective May 22, 2026, with employment beginning on June 1, 2026. Mr. Lundgren succeeds Daniel Vitt, Ph.D.

19.05.2026

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout

Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including a background in multiple sclerosis and central nervous system markets.

19.05.2026

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization – – Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis – NEW YORK, May 19, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael "Mike" W. Bonney, a highly experienced biopharmaceutical executive and board leader, as Chair of its Board of Directors, effective May 16, 2026.

Videolar

No Data

There is no data to display

Press-relizlar

10.06.2026

Immunic to Participate in Investor, Industry and Scientific Conferences in June

27.05.2026

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

19.05.2026

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

13.05.2026

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D.

Immunic, Inc. (IMUX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Immunic, Inc. (IMUX)

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Immunic presents new vidofludimus calcium data at multiple sclerosis conference

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

Videolar

No Data

Press-relizlar

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Immunic presents new vidofludimus calcium data at multiple sclerosis conference

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

Videolar

No Data

Press-relizlar

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Search stocks

Immunic, Inc. (IMUX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Immunic, Inc. (IMUX)

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Immunic presents new vidofludimus calcium data at multiple sclerosis conference

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

Videolar

No Data

Press-relizlar

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Immunic presents new vidofludimus calcium data at multiple sclerosis conference

Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

Videolar

No Data

Press-relizlar

Immunic to Participate in Investor, Industry and Scientific Conferences in June

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update